Knockdown of core binding factorß alters sphingolipid metabolism.

Core binding factor (CBF) is a heterodimeric transcription factor containing one of three DNA-binding proteins of the Runt-related transcription factor family (RUNX1-3) and the non-DNA-binding protein, CBFß. RUNX1 and CBFß are the most common targets of chromosomal rearrangements in leukemia. CBF has been implicated in other cancer types; for example RUNX1 and RUNX2 are implicated in cancers of epithelial origin, including prostate, breast, and ovarian cancers. In these tumors, CBF is involved in maintaining the malignant phenotype and, when highly over-expressed, contributes to metastatic growth in bone. Herein, lentiviral delivery of CBFß-specific shRNAs was used to achieve a 95% reduction of CBFß in an ovarian cancer cell line. This drastic reduction in CBFß expression resulted in growth inhibition that was not associated with a cell cycle block or an increase in apoptosis. However, CBFß silencing resulted in increased autophagy and production of reactive oxygen species (ROS). Since sphingolipid and ceramide metabolism regulates non-apoptotic cell death, autophagy, and ROS production, fumonsin B1 (FB1), an inhibitor of ceramide synthase, was used to alter ceramide production in the CBFß-silenced cells. FB1 treatment inhibited the CBFß-dependent increase in autophagy and provided a modest increase in cell survival. To document alterations to sphingolipids in the CBFß-silenced cells, ceramide, and lactosylceramide levels were directly examined by mass spectrometry. Substantial increases in ceramide species and decreases in lactosylceramides were identified. Altogether, this report provides evidence that CBF transcriptional pathways control cellular survival, at least in part, through sphingolipid metabolism.

Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells.

The Notch receptor pathway provides a paradigm for juxtacrine signaling pathways and controls stem cell function, developmental cell fate decisions, and cellular differentiation. The Notch pathway is constitutively activated in human cancers by chromosomal rearrangements, activating point mutations, or altered expression patterns. Therefore, the Notch pathway is the subject of chemotherapeutic intervention in a variety of human cancers. Notch receptor activation results in the gamma-secretase dependent proteolytic cleavage of the receptor to liberate the Notch intracellular domain that acts to mediate co-activator recruitment to the DNA binding transcription factor, CSL (CBF-1/RBP-Jκ, Su(H), Lag-1). Therapeutic targeting of the Notch pathway by gamma-secretase inhibitors prevents NICD production and regulates CSL-dependent transcriptional activity. To interrogate the loss of CSL activity in breast and prostate cancer cells, we used lentiviral-based shRNA knockdown of CSL. Knockdown of CSL expression was assessed by decreased DNA binding activity and resulted in decreased cell proliferation. In contrast, gamma-secretase inhibitor (GSI) treatment of these prostate and breast cancer cell lines resulted in minimal growth effects. PCR profiling of Notch pathway genes identified expression changes in few genes (Delta-like-1, Deltex-1, LMO2, and SH2D1A) after CSL knockdown. Consistent with differential effects of GSI on cell survival, GSI treatment failed to recapitulate the gene expression changes observed after CSL knockdown. Thus, CSL inhibition may provide a more effective mechanism to inhibit Notch-pathway dependent cancer cell proliferation as compared to GSI treatment.

Association of core-binding factor ß with the malignant phenotype of prostate and ovarian cancer cells.

Core binding factor (CBF) is a transcription factor complex that plays roles in development, stem-cell homeostasis, and human disease. CBF is a heterodimer composed of one of three DNA-binding RUNX proteins plus the non-DNA-binding protein, CBFß. Recent studies have showed that the RUNX factors exhibit complex expression patterns in prostate, breast, and ovarian cancers, and CBF has been implicated in the control of cancer-related genes. However, the biologic roles of CBF in solid tumors have not been fully elucidated. To test whether CBF is required for the malignant phenotype of various epithelial cancers, we used lentiviral delivery of CBFß-specific shRNA to significantly decrease CBFß expression in two prostate cancer cell lines (PPC1 and PC-3) and the SKOV-3 ovarian cancer cell line. We found that knockdown of CBFß significantly inhibited anchorage independent growth of each cell line. Further, CBFß knockdown in PPC1 cells suppressed xenograft tumor growth compared to controls. Mice injected with SKOV-3 ovarian cancer cells knocked-down for CBFß exhibited a survival time similar to control mice. However, human cells recovered from the ascites fluid of these mice showed CBFß expression levels similar to those from mice injected with control SKOV-3 cells, suggesting that CBFß knockdown is incompatible with tumor cell growth. Gene expression profiling of CBFß knockdown cells revealed significant changes in expression in genes involved in various developmental and cell signaling pathways. These data collectively suggest that CBFß is required for malignancy in some human cancers.

Distinctive degradation behaviors of electrospun polyglycolide, poly(DL-lactide-co-glycolide), and poly(L-lactide-co-epsilon-caprolactone) nanofibers cultured with/without porcine smooth muscle cells.

Biodegradable nanofibers have become a popular candidate for tissue engineering scaffolds because of their biomimetic structure that physically resembles the extracellular matrix. For certain tissue regeneration applications, prolonged in vitro culture time for cellular reorganization and tissue remodeling may be required. Therefore, extensive understanding of cellular effects on scaffold degradation is needed. There are only few studies on the degradation of nanofibers, and also the studies on degradation throughout cell culture are rare. In this study, polyglycolide (PGA), poly(DL-lactide-co-glycolide) (PLGA) and poly(L-lactide-co-epsilon-caprolactone) [P(LLA-CL)] were electrospun into nanofibrous meshes. The nanofibers were cultured with porcine smooth muscle cells for up to 3 months to evaluate their degradation behavior and cellular response. The results showed that the degradation rates are in the order of PGA >> PLGA > P(LLA-CL). PGA nanofibers degraded in 3 weeks and supported cell growth only in the first few days. PLGA nanofiber scaffolds facilitated cell growth during the first 30 days after seeding, but cell growth was slow thereafter. P(LLA-CL) nanofibers facilitated long-term (1-3 months) cell growth. mRNA quantification using real-time polymerase chain reaction revealed that some smooth muscle cell markers (alpha-actinin and calponin) and extracellular matrix genes (collagen and integrin) seemed to be downregulated with increased cell culture time. Cell culture significantly increased the degradation rate of PGA nanofibers, whereas the effect on PLGA and P(LLA-CL) nanofibers was limited. We found that the molecular weight of P(LLA-CL) and PLGA nanofibers decreased linearly for up to 100 days. Half lives of PLGA and P(LLA-CL) nanofibers were shown to be 80 and 110 days, respectively. In summary, this is the first study to our knowledge to evaluate long-term polymeric nanofiber degradation in vitro with cell culture. Cell culture accelerated the nanofibrous scaffold degradation to a limited extent. P(LLA-CL) nanofibers could be a good choice as scaffolds for long-term smooth muscle cell culture.

Enhancement of neurite outgrowth using nano-structured scaffolds coupled with laminin.

Cell interactions with scaffolds are important for cell and tissue development in the process of repairing and regeneration of damaged tissue. Scaffolds that mimic extracellular matrix (ECM) surface topography, mechanical stiffness, and chemical composition will be advantageous to promote enhanced cell interactions. Electrospinning can easily produce nano-structured synthetic polymer mats with architecture that structurally resembles the ECM of tissue. Although electrospinning can produce sub-micron fibrous scaffolds, modification of electrospun scaffolds with bioactive molecules is beneficial as this can create an environment that consists of biochemical cues to further promote cell adhesion, proliferation and differentiation. Incorporation of laminin, a neurite promoting ECM protein, onto the nanofibers is an alternative to further mimic the biochemical properties of the nervous tissue to create a biomimetic scaffold. In this study, we investigated the feasibility to functionalize scaffolds by coupling laminin onto poly(L-lactic acid) (PLLA) nanofibers. Laminin was successfully added to nanofibers using covalent binding, physical adsorption or blended electrospinning procedures. PC12 cell viability and neurite outgrowth assays confirmed that the functionalized nanofibers were able to enhance axonal extensions. Significantly, compared to covalent immobilization and physical adsorption, blended electrospinning of laminin and synthetic polymer is a facile and efficient method to modify nanofibers for the fabrication of a biomimetic scaffold. Using these functionalization techniques, nanofibers can be effectively modified with laminin for potential use in peripheral nerve regeneration applications.

Degradation of electrospun nanofiber scaffold by short wave length ultraviolet radiation treatment and its potential applications in tissue engineering.

Development in the field of tissue engineering has brought much attention in the fabrication and preparation of scaffold with biodegradable synthetic polymer nanofibers. Electrospun biodegradable polymeric nanofibers are increasingly being used to fabricate scaffolds for tissue engineering applications as they provide high surface area-to-volume ratio and possess high porosity. One common way to sterilize polymeric nanofiber scaffolds is 254-nm ultraviolet (UV) irradiation. In this study, we aim to evaluate the effects of UV radiation on the degradation in polymeric nanofibers, and then capitalize on UV-induced degradation and UV photolithography in polymeric nanofiber scaffolds for tissue engineering applications. Poly(D,L-lactic-co-glycolic) acid (PLGA, 75:25) and poly(L-lactide-co-epsilon-caprolactone) [P(LLA-CL), 70:30] nanofibrous meshes were produced by electrospinning. The nanofibers were irradiated by commercial germicide UV (lambda=254 nm) lamp for different intervals. We found that UV sterilization induced significant degradation of nanofiber. At 1 h UV irradiation, the average molecular weight of PLGA and P(LLA-CL) nanofibers were reduced by 46% and 35%, respectively, with corresponding reduction in the tensile strength of 26% for PLGA and 28% for P(LLA-CL). Hence, precautions may have to be taken into consideration when sterilizing polymeric nanofibers by UV treatment. UV-induced degradation on nanofibers was applied to fabrication of a three-dimensional (3D) tissue engineering scaffold by UV photolithography. Masked exposure to UV could generate patterned holes (d=100 microm) on the nanofibrous mesh. Cell culture study showed that smooth muscle cells were able to migrate into the holes. This method can be used to fabricate a 3D nanofibrous scaffold with micropores.

Long-term viability of coronary artery smooth muscle cells on poly(L-lactide-co-epsilon-caprolactone) nanofibrous scaffold indicates its potential for blood vessel tissue engineering.

Biodegradable polymer nanofibres have been extensively studied as cell culture scaffolds in tissue engineering. However, long-term in vitro studies of cell-nanofibre interactions were rarely reported and successful organ regeneration using tissue engineering techniques may take months (e.g. blood vessel tissue engineering). Understanding the long-term interaction between cells and nanofibrous scaffolds (NFS) is crucial in material selection, design and processing of the tissue engineering scaffolds. In this study, poly(L-lactide-co-epsilon-caprolactone) [P(LLA-CL)] (70:30) copolymer NFS were produced by electrospinning. Porcine coronary artery smooth muscle cells (PCASMCs) were seeded and cultured on the scaffold to evaluate cell-nanofibre interactions for up to 105 days. A favourable interaction between this scaffold and PCASMCs was demonstrated by cell viability assay, scanning electron microscopy, histological staining and extracellular matrix (ECM) secretion. Degradation behaviours of the scaffolds with or without PCASMC culture were determined by mechanical testing and gel permeation chromatography (GPC). The results showed that the PCASMCs attached and proliferated well on the P(LLA-CL) NFS. Large amount of ECM protein secretion was observed after 50 days of culture. Multilayers of aligned oriented PCASMCs were formed on the scaffold after two months of in vitro culture. In the degradation study, the PCASMCs were not shown to significantly increase the degradation rate of the scaffolds for up to 105 days of culture. The in vitro degradation time of the scaffold could be as long as eight months by extrapolating the results from GPC. These observations further supported the potential use of the P(LLA-CL) nanofibre in blood vessel tissue engineering.

Biodegradable polymer nanofiber mesh to maintain functions of endothelial cells.

Maintaining functions of endothelial cells in vitro is a prerequisite for effective endothelialization of biomaterials as an approach to prevent intimal hyperplasia of small-diameter vascular grafts. The aim of this study was to design suitable nanofiber meshes (NFMs) that further maintain the phenotype and functions of human coronary artery endothelial cells (HCAECs). Collagen-coated random and aligned poly(L-lactic acid)-co-poly(epsilon-caprolactone) (P(LLA-CL)) NFMs were fabricated using electrospinning. Mechanical testing showed that tensile modulus and strength were greater for the aligned P(LLA-CL) NFM than for the random NFM. Spatial distribution of the collagen in the NFMs was visualized by labeling with fluorescent dye. HCAECs grew along the direction of nanofiber alignment and showed elongated morphology that simulated endothelial cells in vivo under blood flow. Both random and aligned P(LLA-CL) NFMs preserved phenotype (expression of platelet endothelial cell adhesion molecule-1, fibronectin, and collagen type IV in protein level) and functions (complementary DNA microarray analysis of 112 genes relevant to endothelial cell functions) of HCAECs. The P(LLA-CL) NFMs are potential materials for tissue-engineered vascular grafts that may enable effective endothelialization.

Fabrication and endothelialization of collagen-blended biodegradable polymer nanofibers: potential vascular graft for blood vessel tissue engineering.

Electrospun collagen-blended poly(L-lactic acid)-co-poly(epsilon-caprolactone) [P(LLA-CL), 70:30] nanofiber may have great potential application in tissue engineering because it mimicks the extracellular matrix (ECM) both morphologically and chemically. Blended nanofibers with various weight ratios of polymer to collagen were fabricated by electrospinning. The appearance of the blended nanofibers was investigated by scanning electron microscopy and transmission electron microscopy. The nanofibers exhibited a smooth surface and a narrow diameter distribution, with 60% of the nanofibers having diameters between 100 and 200 nm. Attenuated total reflectance-Fourier transform infrared spectra and X-ray photoelectron spectroscopy verified the existence of collagen molecules on the surface of nanofibers. Human coronary artery endothelial cells (HCAECs) were seeded onto the blended nanofibers for viability, morphogenesis, attachment, and phenotypic studies. Five characteristic endothelial cell (EC) markers, including four types of cell adhesion molecule and one EC-preferential gene (von Willebrand factor), were studied by reverse transcription-polymerase chain reaction. Results showed that the collagen-blended polymer nanofibers could enhance the viability, spreading, and attachment of HCAECs and, moreover, preserve the EC phenotype. The blending electrospinning technique shows potential in refining the composition of polymer nanofibers by adding various ingredients (e.g., growth factors) according to cell types to fabricate tissue-engineering scaffold, particularly blood vessel-engineering scaffold.

Grafting of gelatin on electrospun poly(caprolactone) nanofibers to improve endothelial cell spreading and proliferation and to control cell Orientation.

We modified the surface of electrospun poly(caprolactone) (PCL) nanofibers to improve their compatibility with endothelial cells (ECs) and to show the potential application of PCL nanofibers as a blood vessel tissue-engineering scaffold. Nonwoven PCL nanofibers (PCL NF) and aligned PCL nanofibers (APCL NF) were fabricated by electrospinning technology. To graft gelatin on the nanofiber surface, PCL nanofibers were first treated with air plasma to introduce -COOH groups on the surface, followed by covalent grafting of gelatin molecules, using water-soluble carbodiimide as the coupling agent. The chemical change in the material surface during surface modification was confirmed by X-ray photoelectron spectroscopy and quantified by colorimetric methods. ECs were cultured to evaluate the cytocompatibility of surface-modified PCL NF and APCL NF. Gelatin grafting can obviously enhance EC spreading and proliferation compared with the original material. Moreover, gelatin-grafted APCL NF readily orients ECs along the fibers whereas unmodified APCL NF does not. Immunostaining micrographs showed that ECs cultured on gelatin-grafted PCL NF were able to maintain the expression of three characteristic markers: platelet-endothelial cell adhesion molecule 1 (PECAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1). The surface-modified PCL nanofibrous material is a potential candidate material in blood vessel tissue engineering.

Fabrication of collagen-coated biodegradable polymer nanofiber mesh and its potential for endothelial cells growth.

Endothelialization of biomaterials is a promising way to prevent intimal hyperplasia of small-diameter vascular grafts. The aim of this study was to design a nanofiber mesh (NFM) that facilitates viability, attachment and phenotypic maintenance of human coronary artery endothelial cells (HCAECs). Collagen-coated poly(L-lactic acid)-co-poly(epsilon-caprolactone) P(LLA-CL 70:30) NFM with a porosity of 64-67% and a fiber diameter of 470+/-130 nm was fabricated using electrospinning followed by plasma treatment and collagen coating. The structure of the NFM was observed by SEM and TEM, and mechanical property was studied by tensile test. The presence of collagen on the P(LLA-CL) NFM surface was verified by X-ray photoelectron spectroscopy (XPS) and quantified by colorimetric method. Spatial distribution of the collagen in the NFM was visualized by labelling with fluorescent probe. The collagen-coated P(LLA-CL) NFM enhanced the spreading, viability and attachment of HCAECs, and moreover, preserve HCAEC's phenotype. The P(LLA-CL) NFM is a potential material for tissue engineered vascular graft.

Surface engineering of electrospun polyethylene terephthalate (PET) nanofibers towards development of a new material for blood vessel engineering.

Non-woven polyethylene terephthalate nanofiber mats (PET NFM) were prepared by electrospinning technology and were surface modified to mimic the fibrous proteins in native extracellular matrix towards constructing a biocompatible surface for endothelial cells (ECs). The electrospun PET NFM was first treated in formaldehyde to yield hydroxyl groups on the surface, followed by the grafting polymerization of methacrylic acid (MAA) initiated by Ce(IV). Finally, the PMAA-grafted PET NFM was grafted with gelatin using water-soluble carbodiimide as coupling agent. Plane PET film was also surface modified and characterized for basic understanding of the surface modification process. The grafting of PMAA and gelatin on PET surface was confirmed by XPS spectroscopy and quantitatively analyzed by colorimetric methods. ECs were cultured on the original and gelatin-modified PET NFM and the cell morphology, proliferation and viability were studied. Three characteristic surface makers expressed by ECs were studied using immuno-florescent microscopy. The gelatin grafting method can obviously improve the spreading and proliferation of the ECs on the PET NFM, and moreover, can preserve the EC's phenotype.

Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors.

Our aim was to evaluate the feasibility and efficacy of tumor necrosis factor-alpha gene therapy in preventing bladder tumor recurrence using an orthotopic model of bladder cancer. We transiently transfected a murine bladder cancer cell line MB49 with pBud-TNF-alpha using a transfection system consisting of the cationic liposome N-(1-(2,3-dioleoyloxyl)propyl)-N,N,N-trimethylammoniummethyl sulfate (DOTAP) plus methyl-beta-cyclodextrin solubilized cholesterol (MBC). MB49 cells produced 893.7+/-24.0 pg/ml of TNF-alpha 2 days after transfection. Cell growth was inhibited, apoptosis was induced and MHC class I, B7.1 and Fas expression on the MB49 cells were increased. In vivo, an orthotopic murine bladder cancer model was established by intravesical instillation of bladder cancer cells after transurethral cauterization of the mouse bladder mucosa. TNF-alpha gene transfer was initiated 2 days after the tumor inoculation, when the tumor burden was small, and given twice per week for 3 weeks. RT-PCR showed TNF-alpha mRNA was observed to increase after the first instillation and then return to basal level 1 month after the sixth instillation. Histology revealed that TNF-alpha gene transfer decreases the bladder tumor incidence from 75% for the control group to 25% for the treated group. Increased level of T lymphocytes and NK cells was found in the TNF-alpha transfected bladders. In situ cytokine gene transfer provides significant protection against tumor growth. This approach may be useful to reduce the incidence of a subsequent tumor after endoscopic resection when used for prophylaxis.

SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells.

p130 is a member of the retinoblastoma family of pocket proteins, which includes pRB and p107. Unlike pRB and p107, p130 protein levels decrease dramatically following its hyperphosphorylation starting in the mid-G1 phase of the cell cycle. However, the mechanism leading to p130 downregulation is unknown. We have found that the proteasome inhibitor, lactacystin, inhibited p130 downregulation in T98G cells progressing through the G1/S transition and S phase and that p130 is multiubiquitylated in 293 cells. We have previously shown that ectopic expression of both cyclin D and E induces phosphorylation and downregulation of p130. Since the SKP1/Cul1/SKP2 E3 ubiquitin ligase complex mediates ubiquitylation of substrates previously phosphorylated by cyclin-dependent kinases, we investigated the potential role of this ubiquitin ligase in mediating p130 downregulation. We found that p130 interacts with SKP1, Cul-1 and SKP2 in human 293 cells. We also found that ectopic coexpression of SKP2 and p130 leads to dose-dependent downregulation of p130, reduces p130 protein half-life and induces p130 ubiquitylation in these cells. Moreover, adenoviral-mediated expression of SKP2 accelerates downregulation of endogenous hyperphosphorylated p130 in mitogen-stimulated T98G cells and primary WI38 fibroblasts. We conclude that p130 is a substrate of the SCF(SKP2) ubiquitin ligase and this E3 ligase regulates p130 abundance during the cell cycle.

G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression.

Mitogenic stimulation leads to activation of G(1) cyclin-dependent kinases (CDKs), which phosphorylate pocket proteins and trigger progression through the G(0)/G(1) and G(1)/S transitions of the cell cycle. However, the individual role of G(1) cyclin-CDK complexes in the coordinated regulation of pocket proteins and their interaction with E2F family members is not fully understood. Here we report that individually or in concert cyclin D1-CDK and cyclin E-CDK complexes induce distinct and coordinated phosphorylation of endogenous pocket proteins, which also has distinct consequences in the regulation of pocket protein interactions with E2F4 and the expression of p107 and E2F1, both E2F-regulated genes. The up-regulation of these two proteins and the release of p130 and pRB from E2F4 complexes allows formation of E2F1 complexes not only with pRB but also with p130 and p107 as well as the formation of p107-E2F4 complexes. The formation of these complexes occurs in the presence of active cyclin D1-CDK and cyclin E-CDK complexes, indicating that whereas phosphorylation plays a role in the abrogation of certain pocket protein/E2F interactions, these same activities induce the formation of other complexes in the context of a cell expressing endogenous levels of pocket and E2F proteins. Of note, phosphorylated p130 "form 3," which does not interact with E2F4, readily interacts with E2F1. Our data also demonstrate that ectopic overexpression of either cyclin is sufficient to induce mitogen-independent growth in human T98G and Rat-1 cells, although the effects of cyclin D1 require downstream activation of cyclin E-CDK2 activity. Interestingly, in T98G cells, cyclin D1 induces cell cycle progression more potently than cyclin E. This suggests that cyclin D1 activates pathways independently of cyclin E that ensure timely progression through the cell cycle.